Copyright
©The Author(s) 2017.
World J Gastrointest Pharmacol Ther. May 6, 2017; 8(2): 137-146
Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.137
Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.137
Table 2 Sustained virological response by genotype and treatment regimen
| Treatment regimen | Patients in each | SVR |
| Genotype 1 | ||
| SMV and SOF | 149 (41.2) | 139 (93.3) |
| SMV and DCV | 7 (1.9) | 7 (100) |
| SOF and DCV | 15 (4.1) | 15 (100) |
| OMV, PTV/r, and DSV | 91 (25.1) | 86 (94.5) |
| SOF and LDV | 100 (27.6) | 95 (95.0) |
| Total | 362 (100) | 342 (94.5) |
| Genotype 2 | ||
| SOF and DCV | 5 (45.5) | 5 (100) |
| SOF | 5 (45.5) | 5 (100) |
| SOF and LDV | 1 (9.1) | 1 (100) |
| Total | 11 (100) | 11 (100) |
| Genotype 3 | ||
| SOF and DCV | 37 (82.2) | 34 (91.9) |
| SOF | 5 (11.1) | 5 (100) |
| SOF and LDV | 3 (6.7) | 3 (100) |
| Total | 45 (100) | 42 (93.3) |
| Genotype 4 | ||
| SMV and SOF | 19 (43.2) | 18 (94.7) |
| SOF | 1 (2.3) | 1 (100) |
| OMV and PTV/r | 13 (29.5) | 12 (92.3) |
| SOF and LDV | 11 (25.0) | 11 (100) |
| Total | 44 (100) | 42 (95.5) |
- Citation: Ramos H, Linares P, Badia E, Martín I, Gómez J, Almohalla C, Jorquera F, Calvo S, García I, Conde P, Álvarez B, Karpman G, Lorenzo S, Gozalo V, Vásquez M, Joao D, de Benito M, Ruiz L, Jiménez F, Sáez-Royuela F, Asociación Castellano y Leonesa de Hepatología (ACyLHE). Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting. World J Gastrointest Pharmacol Ther 2017; 8(2): 137-146
- URL: https://www.wjgnet.com/2150-5349/full/v8/i2/137.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v8.i2.137